Dr. Lal Pathlabs Ltd. News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Dr. Lal Pathlabs Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Dr. Lal Pathlabs Ltd.
Rating: 3
Author: Geojit BNP Paribas

Keep track of all breaking news and updates on Dr. Lal Pathlabs Ltd. from all sources in a single place.

Dr. Lal Pathlabs Ltd.

07 Oct 2025, 02:41PM

3071.90

-2.37%

Company Update

Dr. Lal PathLabs Ltd - 539524 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, …

BSE India

Attached

pdf

Dr. Lal Pathlabs Ltd.

26 Sep 2025

3071.90

-2.37%

SAST

Dr. Lal PathLabs Ltd - 539524 - Closure of Trading Window

BSE India

Attached

pdf

Dr. Lal Pathlabs Ltd.

24 Sep 2025

3071.90

-2.37%

Company Update

Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements

BSE India

Attached

pdf

Dr. Lal Pathlabs Ltd.

14 Sep 2025

3071.90

-2.37%

Eye helpline launched to connect patients nationwide with Delhi doctors

Business Standard

Making eye care accessible to citizens, a team of leading ophthalmologists in Delhi have launched a national eye helpline number to connect doctors with patients from all over the country. The initiative, spearheaded under the banner of Sight Sarthi India Foundation, a not-for-profit organisation, promises free telephonic and video consultations for anyone across the country struggling with eye problems. Headed by Dr Ikeda Lal, cornea, cataract and refractive surgeon and medical director at Delhi Eye Centre, the helpline is set to become a lifeline for millions - especially those in remote towns and villages who often struggle to access quality ophthalmic care. With a dedicated team of leading ophthalmologists from Delhi, the project is designed to break barriers of geography, cost, and access. From cataract and refractive errors to preventable blindness, millions either delay or avoid treatment due to lack of access or high cost of travel, Dr Lal said. "The newly launched helplin

Dr. Lal Pathlabs Ltd. has an average target of 3111.40 from 5 brokers.

Dr. Lal Pathlabs Ltd.

02 Sep 2025

3071.90

-2.37%

DR. LAL PATHLABS LIMITED

Hold: Dr. Lal Pathlabs Ltd.

Target

Geojit BNP Paribas

*over or under performance to benchmark index Dr Lal PathLabs Ltd (DLPL) provides diagnostic tests and services globally. As of December 2024, DLPL had 280 clinical laboratories, including a national reference lab...

Dr. Lal Pathlabs Ltd. is trading below its 30 day SMA of 3262.4

Dr. Lal Pathlabs Ltd.

26 Aug 2025

3071.90

-2.37%

Company Update

Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - …

BSE India

Attached

pdf

Dr. Lal Pathlabs Ltd.

22 Aug 2025

3071.90

-2.37%

Company Update

Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Attached

pdf

Dr. Lal Pathlabs Ltd.

20 Aug 2025

3071.90

-2.37%

Dr. Lal Path Labs rises 3% on adopting new AI cancer diagnostic tool

Business Standard

Dr. Lal Path Labs shares rose 3.2 per cent on Wednesday, after it became the first laboratory in the country to adopt a deep learning-based AI module to detect lymph node metastas